Coloplast A/S (CLPBY) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Coloplast is projected to report quarterly results before market open on Tuesday, May 12, with analysts expecting EPS of $0.09 and revenue of $1.108 billion.
• Analyst sentiment is negative — the consensus rating is Reduce, with three Hold ratings and one Sell, and Goldman Sachs recently lowered its rating to "strong sell."
• Shares trade around $6.30 (12‑month range $6.10–$11.44) with a market cap of $14.2 billion and a P/E of 23.33, and analysts expect $0 EPS for the current and next fiscal years.

Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) is projected to announce its results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $1.1081 billion for the quarter.

Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) last issued its quarterly earnings data on Friday, February 6th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. Coloplast A/S had a net margin of 14.35% and a return on equity of 27.87%. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.12 billion. On average, analysts expect Coloplast A/S to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Coloplast A/S Stock Performance

Shares of CLPBY stock opened at $6.30 on Tuesday. Coloplast A/S has a 12 month low of $6.10 and a 12 month high of $11.44. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.30 and a quick ratio of 0.81. The firm has a market capitalization of $14.20 billion, a P/E ratio of 23.33, a P/E/G ratio of 2.02 and a beta of 0.15. The company's fifty day moving average price is $6.89 and its two-hundred day moving average price is $8.10.

Analysts Set New Price Targets

A number of equities analysts have commented on CLPBY shares. Sanford C. Bernstein upgraded shares of Coloplast A/S to a "hold" rating in a report on Wednesday, January 28th. The Goldman Sachs Group lowered shares of Coloplast A/S from a "hold" rating to a "strong sell" rating in a research note on Tuesday, April 7th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Coloplast A/S has a consensus rating of "Reduce".

Coloplast A/S Company Profile

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast's offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.